TNSN07275A1 - Derives de triazole substitues, servant d'antagonistes d'ocytocine - Google Patents
Derives de triazole substitues, servant d'antagonistes d'ocytocineInfo
- Publication number
- TNSN07275A1 TNSN07275A1 TNP2007000275A TNSN07275A TNSN07275A1 TN SN07275 A1 TNSN07275 A1 TN SN07275A1 TN P2007000275 A TNP2007000275 A TN P2007000275A TN SN07275 A TNSN07275 A TN SN07275A TN SN07275 A1 TNSN07275 A1 TN SN07275A1
- Authority
- TN
- Tunisia
- Prior art keywords
- ocytocin
- antagonists
- triazole derivatives
- substituted triazole
- substituted
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/12—Drugs for genital or sexual disorders; Contraceptives for climacteric disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/10—Drugs for disorders of the endocrine system of the posterior pituitary hormones, e.g. oxytocin, ADH
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Endocrinology (AREA)
- Reproductive Health (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Epidemiology (AREA)
- Ophthalmology & Optometry (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Diabetes (AREA)
- Biomedical Technology (AREA)
- Urology & Nephrology (AREA)
- Gastroenterology & Hepatology (AREA)
- Gynecology & Obstetrics (AREA)
- Hospice & Palliative Care (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
La présente invention concerne des triazoles substitués de formule (I), leurs utilisations, des procédés pour leur préparation et des compositions contenant lesdits composés. Ces inhibiteurs sont utiles dans divers domaines thérapeutiques, y compris un dysfonctionnement sexuel.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GBGB0501190.3A GB0501190D0 (en) | 2005-01-20 | 2005-01-20 | Novel pharmaceuticals |
PCT/IB2006/000118 WO2006077496A1 (fr) | 2005-01-20 | 2006-01-11 | Utilisation de derives de triazole substitues comme antagonistes de l'oxytocine |
Publications (1)
Publication Number | Publication Date |
---|---|
TNSN07275A1 true TNSN07275A1 (fr) | 2008-12-31 |
Family
ID=34259404
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
TNP2007000275A TNSN07275A1 (fr) | 2005-01-20 | 2007-07-19 | Derives de triazole substitues, servant d'antagonistes d'ocytocine |
Country Status (32)
Country | Link |
---|---|
US (5) | US7557131B2 (fr) |
EP (1) | EP1841758B1 (fr) |
JP (1) | JP4124805B1 (fr) |
KR (1) | KR100936854B1 (fr) |
CN (1) | CN101107243B (fr) |
AP (1) | AP2007004047A0 (fr) |
AR (1) | AR055303A1 (fr) |
AT (1) | ATE449091T1 (fr) |
AU (1) | AU2006207300B2 (fr) |
BR (1) | BRPI0606463A2 (fr) |
CA (1) | CA2595569C (fr) |
CR (1) | CR9219A (fr) |
DE (1) | DE602006010508D1 (fr) |
DK (1) | DK1841758T3 (fr) |
DO (1) | DOP2006000014A (fr) |
EA (1) | EA200701328A1 (fr) |
ES (1) | ES2334517T3 (fr) |
GB (1) | GB0501190D0 (fr) |
GT (1) | GT200600024A (fr) |
HK (1) | HK1113927A1 (fr) |
IL (1) | IL184148A (fr) |
MA (1) | MA29160B1 (fr) |
MX (1) | MX2007008757A (fr) |
NL (1) | NL1030961C2 (fr) |
NO (1) | NO338420B1 (fr) |
PA (1) | PA8660401A1 (fr) |
PE (1) | PE20060875A1 (fr) |
TN (1) | TNSN07275A1 (fr) |
TW (1) | TW200637847A (fr) |
UY (1) | UY29339A1 (fr) |
WO (1) | WO2006077496A1 (fr) |
ZA (1) | ZA200705718B (fr) |
Families Citing this family (23)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH06284516A (ja) * | 1993-03-31 | 1994-10-07 | Mitsubishi Electric Corp | 電気車制御装置 |
AP2007004047A0 (en) | 2005-01-20 | 2007-06-30 | Pfizer Ltd | Substituted triazole derivatives as oxtocin antagonists |
GB0504556D0 (en) * | 2005-03-04 | 2005-04-13 | Pfizer Ltd | Novel pharmaceuticals |
AU2006255465A1 (en) * | 2005-06-09 | 2006-12-14 | Merck Frosst Canada Ltd | Azacyclohexane derivatives as inhibitors of stearoyl-coenzyme a delta-9 desaturase |
GB0607196D0 (en) * | 2006-04-11 | 2006-05-17 | Prosidion Ltd | G-protein coupled receptor agonists |
US20090170828A1 (en) * | 2006-06-12 | 2009-07-02 | Elise Isabel | Azetidine Derivatives as Inhibitors of Stearoyl-Coenzyme a Delta-9 Desaturase |
EP2032570A4 (fr) * | 2006-06-13 | 2010-10-27 | Merck Frosst Canada Ltd | Dérivés de l'azacyclopentane utilisés en tant qu'inhibiteurs de la stéaroyl-coenzyme a delta-9 désaturase |
EP2141994A4 (fr) * | 2007-04-26 | 2011-05-18 | Avalon Pharmaceuticals | Composés polycycliques et leurs utilisations |
AU2009210296B2 (en) * | 2008-01-31 | 2013-11-14 | Sanofi | Cyclic azaindole-3-carboxamides, their preparation and their use as pharmaceuticals |
AU2009210297B2 (en) | 2008-01-31 | 2013-11-21 | Sanofi | Cyclic indole-3-carboxamides, their preparation and their use as pharmaceuticals |
MY171483A (en) * | 2012-07-16 | 2019-10-15 | Fibrogen Inc | Process for making isoquinoline compounds |
US10570146B2 (en) * | 2014-07-25 | 2020-02-25 | Northeastern University | Urea/carbamates FAAH MAGL or dual FAAH/MAGL inhibitors and uses thereof |
JOP20190072A1 (ar) * | 2016-10-13 | 2019-04-07 | Glaxosmithkline Ip Dev Ltd | مشتقات 1، 3 سيكلوبوتان ثنائي الاستبدال أو آزيتيدين كمثبطات للإنزيم المخلق للبروستاجلاندين d المكون للدم |
WO2018091687A1 (fr) | 2016-11-18 | 2018-05-24 | Integrative Research Laboratories Sweden Ab | Nouveaux dérivés d'azétidine utiles en tant que modulateurs de la neurotransmission catécholaminergique corticale |
US10889569B2 (en) | 2016-12-21 | 2021-01-12 | Jiangsu Hengrui Medicine Co., Ltd. | Condensed ring group azacyclobutyl triazole derivative, preparation method therefor and use thereof in medicine |
AU2017389819B2 (en) * | 2016-12-28 | 2021-05-27 | Jiangsu Hengrui Medicine Co., Ltd. | Azabicyclo-substituted triazole derivative, preparation method thereof, and application of same in medicine |
CN111094273B (zh) * | 2018-06-20 | 2022-04-12 | 江苏恒瑞医药股份有限公司 | 催产素受体抑制剂的晶型及其制备方法 |
WO2019242642A1 (fr) * | 2018-06-20 | 2019-12-26 | 江苏恒瑞医药股份有限公司 | Sel pharmaceutiquement acceptable et forme cristalline d'un inhibiteur d'otr et procédé de préparation associé |
CN111902406B (zh) * | 2018-06-27 | 2022-11-18 | 江苏恒瑞医药股份有限公司 | 氮杂双环基取代的***类衍生物的可药用盐、晶型及制备方法 |
CN113004250B (zh) * | 2019-12-19 | 2022-07-26 | 上海森辉医药有限公司 | 一种制备取代的***衍生物的方法 |
CN113582818B (zh) * | 2021-08-30 | 2023-08-01 | 上海日异生物科技有限公司 | 一种3-卤-2-烷基苯酚的合成方法 |
WO2023156386A2 (fr) * | 2022-02-16 | 2023-08-24 | Duke Street Bio Limited | Composé pharmaceutique |
CN114805161B (zh) * | 2022-06-14 | 2023-08-25 | 南通华祥医药科技有限公司 | 一种3-氟丫丁啶盐酸盐的制备方法 |
Family Cites Families (27)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4554276A (en) | 1983-10-03 | 1985-11-19 | Pfizer Inc. | 2-Amino-5-hydroxy-4-methylpyrimidine derivatives |
US5053411A (en) | 1989-04-20 | 1991-10-01 | Anaquest, Inc. | N-aryl-N-[4-(1-heterocyclicalkyl)piperidinyl]amides and pharmaceutical compositions and methods employing such compounds |
DE4124942A1 (de) | 1991-07-27 | 1993-01-28 | Thomae Gmbh Dr K | 5-gliedrige heterocyclen, verfahren zu ihrer herstellung und diese verbindungen enthaltende arzneimittel |
DE4302051A1 (de) | 1993-01-26 | 1994-07-28 | Thomae Gmbh Dr K | 5-gliedrige Heterocyclen, Verfahren zu ihrer Herstellung und diese Verbindungen enthaltende Arzneimittel |
AU715658B2 (en) | 1996-04-03 | 2000-02-10 | Merck & Co., Inc. | Inhibitors of farnesyl-protein transferase |
EP0904076A1 (fr) | 1996-04-03 | 1999-03-31 | Merck & Co., Inc. | Inhibiteurs de la farnesyl-proteine transferase |
JP2000509371A (ja) | 1996-04-03 | 2000-07-25 | メルク エンド カンパニー インコーポレーテッド | ファルネシル―タンパク質トランスフェラーゼ阻害剤 |
CA2249665A1 (fr) | 1996-04-03 | 1997-10-09 | Merck & Co., Inc. | Inhibiteurs de la farnesyl-proteine transferase |
WO1998028980A1 (fr) | 1996-12-30 | 1998-07-09 | Merck & Co., Inc. | Inhibiteurs de farnesyl-proteine transferase |
EA200000526A1 (ru) | 1997-12-16 | 2000-12-25 | Пфайзер Продактс Инк. | Комбинация, эффективная для лечения импотенции |
AU763976B2 (en) | 1999-07-23 | 2003-08-07 | Shionogi & Co., Ltd. | Th2 differentiation inhibitors |
CN1195522C (zh) | 1999-10-15 | 2005-04-06 | 弗·哈夫曼-拉罗切有限公司 | 苯并二氮杂䓬衍生物 |
JP4883862B2 (ja) | 1999-11-15 | 2012-02-22 | ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ | ファルネシルトランスフェラーゼ阻害剤としてのトリアゾール類 |
WO2001076582A1 (fr) | 2000-04-05 | 2001-10-18 | Shionogi & Co., Ltd. | Micro-emulsions huile dans eau contenant des composes tricycliques ou des preconcentres de ceux-ci |
PL359340A1 (en) * | 2000-05-19 | 2004-08-23 | Triazole derivatives | |
US20030216385A1 (en) | 2000-05-19 | 2003-11-20 | Takahiko Tobe | Triazole derivatives |
WO2003093242A2 (fr) | 2001-10-03 | 2003-11-13 | Pharmacia Corporation | Composes polycycliques a 5 elements substitues pour l'inhibition selective de la cascade de reactions dans la coagulation sanguine |
GB0130677D0 (en) | 2001-12-21 | 2002-02-06 | Glaxo Group Ltd | Medicaments and novel compounds |
GB0208579D0 (en) | 2002-04-13 | 2002-05-22 | British Biotech Pharm | Antibacterial agents |
GB0224919D0 (en) | 2002-10-25 | 2002-12-04 | Pfizer Ltd | Triazole compounds useful in therapy |
US20040167188A1 (en) | 2003-02-14 | 2004-08-26 | Zhili Xin | Protein-tyrosine phosphatase inhibitors and uses thereof |
US7169797B2 (en) | 2003-02-14 | 2007-01-30 | Abbott Laboratories | Protein-tyrosine phosphatase inhibitors and uses thereof |
BRPI0414663A (pt) * | 2003-09-22 | 2006-11-21 | Pfizer | derivados triazol substituìdos como antagonistas de oxitocina |
OA13347A (en) | 2003-12-22 | 2007-04-13 | Pfizer | Triazole derivatives as vasopressin antagonists. |
WO2005082866A2 (fr) * | 2004-02-20 | 2005-09-09 | Pfizer Limited | Derives de triazole substitues utilises en tant qu'antagonistes de l'oxytocine |
WO2005105779A1 (fr) | 2004-04-28 | 2005-11-10 | Pfizer Limited | Derives 3-heterocyclyl-4-phenyl-triazole comme inhibiteurs de la vasopressine par recepteur |
AP2007004047A0 (en) | 2005-01-20 | 2007-06-30 | Pfizer Ltd | Substituted triazole derivatives as oxtocin antagonists |
-
2005
- 2005-01-11 AP AP2007004047A patent/AP2007004047A0/xx unknown
- 2005-01-20 GB GBGB0501190.3A patent/GB0501190D0/en not_active Ceased
-
2006
- 2006-01-11 CA CA2595569A patent/CA2595569C/fr active Active
- 2006-01-11 KR KR1020077016553A patent/KR100936854B1/ko active IP Right Grant
- 2006-01-11 AT AT06710261T patent/ATE449091T1/de not_active IP Right Cessation
- 2006-01-11 EA EA200701328A patent/EA200701328A1/ru unknown
- 2006-01-11 DK DK06710261.6T patent/DK1841758T3/da active
- 2006-01-11 MX MX2007008757A patent/MX2007008757A/es active IP Right Grant
- 2006-01-11 CN CN2006800028617A patent/CN101107243B/zh active Active
- 2006-01-11 EP EP06710261A patent/EP1841758B1/fr active Active
- 2006-01-11 DE DE602006010508T patent/DE602006010508D1/de active Active
- 2006-01-11 AU AU2006207300A patent/AU2006207300B2/en active Active
- 2006-01-11 BR BRPI0606463-9A patent/BRPI0606463A2/pt not_active IP Right Cessation
- 2006-01-11 ES ES06710261T patent/ES2334517T3/es active Active
- 2006-01-11 JP JP2007551766A patent/JP4124805B1/ja active Active
- 2006-01-11 WO PCT/IB2006/000118 patent/WO2006077496A1/fr active Application Filing
- 2006-01-17 DO DO2006000014A patent/DOP2006000014A/es unknown
- 2006-01-17 PE PE2006000072A patent/PE20060875A1/es not_active Application Discontinuation
- 2006-01-18 UY UY29339A patent/UY29339A1/es active IP Right Grant
- 2006-01-18 AR ARP060100188A patent/AR055303A1/es unknown
- 2006-01-19 GT GT200600024A patent/GT200600024A/es unknown
- 2006-01-19 NL NL1030961A patent/NL1030961C2/nl active Search and Examination
- 2006-01-19 TW TW095102071A patent/TW200637847A/zh unknown
- 2006-01-20 PA PA20068660401A patent/PA8660401A1/es unknown
- 2006-01-20 US US11/335,940 patent/US7557131B2/en active Active
-
2007
- 2007-06-21 IL IL184148A patent/IL184148A/en active IP Right Grant
- 2007-07-02 CR CR9219A patent/CR9219A/es not_active Application Discontinuation
- 2007-07-11 ZA ZA200705718A patent/ZA200705718B/xx unknown
- 2007-07-19 TN TNP2007000275A patent/TNSN07275A1/fr unknown
- 2007-07-20 MA MA30089A patent/MA29160B1/fr unknown
- 2007-08-14 NO NO20074177A patent/NO338420B1/no unknown
-
2008
- 2008-03-19 HK HK08103169.1A patent/HK1113927A1/xx unknown
-
2009
- 2009-05-15 US US12/466,785 patent/US8207198B2/en active Active
-
2012
- 2012-05-23 US US13/478,384 patent/US9023872B2/en active Active
-
2015
- 2015-04-20 US US14/691,319 patent/US9394278B2/en active Active
-
2016
- 2016-06-28 US US15/195,480 patent/US10150752B2/en active Active
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
TNSN07275A1 (fr) | Derives de triazole substitues, servant d'antagonistes d'ocytocine | |
TNSN07022A1 (fr) | Derives de pyridine | |
TN2009000450A1 (fr) | Derives de pyridine | |
MA29926B1 (fr) | Derives de pyrazine | |
MA31766B1 (fr) | Composés organiques | |
MA30405B1 (fr) | Derives de 4-benzylphtalazinone substitues en 2 en tant qu'antagonistes des histamines hl et h3 | |
MA31894B1 (fr) | Composes organiques | |
MXPA05011166A (es) | Antagonistas del receptor del peptido relacionado con el gen de la calcitonina. | |
MA33178B1 (fr) | Pipéridines substituées comme antagonistes de ccr3 | |
MA32466B1 (fr) | Derives de triazole utiles pour le traitement de maladies | |
EP1615914A4 (fr) | Antagonistes des recepteurs de cgrp | |
TNSN07349A1 (fr) | Derives de n-(n-sulfonylaminomethyl) cyclopropanecarboxamide utiles pour le traitement de la douleur | |
MA31574B1 (fr) | Dérivés de pyrazole et leur utilisation comme inhibiteurs de raf | |
DE602005020655D1 (de) | Carboxamid-spirolactam-cgrp-rezeptor-antagonisten | |
MA27560A1 (fr) | Nouveaux derives de fluorglycoside heterocycliques, produits pharmaceutiques contenant ces composes et leur utilisation | |
MA30988B1 (fr) | Composes destines a inhiber la progression mitotique | |
MA30351B1 (fr) | Composes de tetrahydropyridothienopyrimidine et leurs procedes d'utilisation | |
ATE503755T1 (de) | Cgrp-rezeptorantagonisten | |
MA30166B1 (fr) | Imidazoles substitues et leur utilisation comme pesticides. | |
WO2006041830A3 (fr) | Antagonistes du recepteur de cgrp | |
MA33836B1 (fr) | Compositions pharmaceutiques contenant des ligands des récepteurs sigma | |
TNSN08137A1 (fr) | Derives de carboxamides servant d'antagonistes des recepteurs muscariniques | |
MA31761B1 (fr) | Nouveaux inhibiteurs de seh et leur utilisation | |
TNSN01126A1 (fr) | Imidazoles substitues nouveaux, procede pour leur preparation et compositions les contenant | |
TW200716547A (en) | Piperidin-4-yl-amide derivatives |